A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small...

por Garon, Edward B, Neidhart, Jeffrey D, Gabrail, Nashat Y, de Oliveira, Moacyr R, Balkissoon, Jai, Kabbinavar, Fairooz
Publicado 2016

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

por Salama, Carlos, Han, Jian, Yau, Linda, Reiss, William G., Kramer, Benjamin, Neidhart, Jeffrey D., Criner, Gerard J., Kaplan-Lewis, Emma, Baden, Rachel, Pandit, Lavannya, Cameron, Miriam L., Garcia-Diaz, Julia, Chávez, Victoria, Mekebeb-Reuter, Martha, Lima de Menezes, Ferdinando, Shah, Reena, González-Lara, Maria F., Assman, Beverly, Freedman, Jamie, Mohan, Shalini V.
Publicado 2020